公开(公告)号：WO2012135646A3

公开(公告)日：2014-04-10

申请号：PCT/US2012031502

申请日：2012-03-30

Applicant: ALVINE PHARMACEUTICALS INC ,  KUMAR PAWAN

Inventor： KUMAR PAWAN

IPC: A61K38/54 ,  A23L29/00

CPC classification number: C12N9/6405 ,  A23L29/06 ,  A23V2002/00 ,  A61K38/48 ,  A61K38/4806 ,  A61K38/4813 ,  A61K38/4873 ,  A61K2300/00

Abstract: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.

Abstract translation: 分离出来自昆虫（包括面粉甲虫）的麸质降解蛋白酶，并且纯化的和重组形式可以用于使麸质食物对于面筋不耐受的患者来说是安全的。

公开(公告)号：WO2013134736A1

公开(公告)日：2013-09-12

申请号：PCT/US2013/030044

申请日：2013-03-08

Applicant: NUSIRT SCIENCES, INC. ,  ZEMEL, Michael ,  GRINDSTAFF II, E., Douglas

Inventor： ZEMEL, Michael ,  GRINDSTAFF II, E., Douglas

IPC: A61K38/54

CPC classification number: A61K31/4415 ,  A23L33/15 ,  A23L33/175 ,  A23V2002/00 ,  A61K31/155 ,  A61K31/191 ,  A61K31/194 ,  A61K31/198 ,  A23V2200/332 ,  A23V2250/0628 ,  A23V2250/7052 ,  A61K2300/00

Abstract: The present invention provides for compositions, methods and kits for regulating energy metabolism. In one aspect, the invention provides for compositions that comprise a combination of (a) branched chain amino acids, such as leucine, and (b) vitamin B6, or any precursors or metabolites of (a) or (b). These combinations may be synergistic and/or effective for reducing weight or adipose volume. In another aspect, the invention provides for methods of regulating energy metabolism by the administration of one or more compositions comprising branched chain amino acids and vitamin B6. The invention also provides for kits comprising compositions of branched chain amino acids and vitamin B6 packaged in an oral dose form with usage instructions.

Abstract translation: 本发明提供了用于调节能量代谢的组合物，方法和试剂盒。 一方面，本发明提供了包含（a）支链氨基酸如亮氨酸和（b）维生素B6或（a）或（b）的任何前体或代谢物的组合的组合物。 这些组合对于减轻体重或脂肪体积可以是协同的和/或有效的。 另一方面，本发明提供了通过施用包含支链氨基酸和维生素B6的一种或多种组合物来调节能量代谢的方法。 本发明还提供了包含以使用说明书口服剂量形式包装的支链氨基酸和维生素B6的组合物的试剂盒。

公开(公告)号：WO2012033459A1

公开(公告)日：2012-03-15

申请号：PCT/SE2011/051089

申请日：2011-09-08

Applicant: ANARA AB ,  PIERZYNOWSKI, Stefan ,  PRYKHOD'KO, Olena ,  WESTRÖM, Björn

Inventor： PIERZYNOWSKI, Stefan ,  PRYKHOD'KO, Olena ,  WESTRÖM, Björn

IPC: A61K38/54 ,  A61P1/00 ,  G01N33/48

CPC classification number: A61K38/54 ,  A61K38/465 ,  A61K38/47 ,  A61K38/48 ,  A61K2300/00

Abstract: The present invention provides a method to induce maturation of an immature GI-tract, such as intestine, e.g. small intestine, the method comprising the steps of administering a mixture of enzymes to the immature GI-tract, said enzymes having a pancreatic activity or action, and/or pancreatic like activity or action, and analysing the maturation process of the GI-tract to monitor said maturation process. Provided herein are also uses and kits to provide for GI-tract maturation.

Abstract translation: 本发明提供诱导未成熟胃肠道成熟的方法，例如肠，例如肠。 小肠，该方法包括以下步骤：向未成熟胃肠道施用酶混合物，所述酶具有胰腺活性或作用，和/或胰腺样活性或作用，并分析胃肠道的成熟过程 监控成熟过程。 本文还提供用于GI道成熟的用途和试剂盒。

公开(公告)号：WO2005077046A3

公开(公告)日：2009-03-26

申请号：PCT/US2005004048

申请日：2005-02-10

Applicant: NEW HORIZONS DIAGNOSTICS INC ,  UNIV ROCKEFELLER ,  LOOMIS LAWRENCE ,  FISCHETTI VINCENT

Inventor： LOOMIS LAWRENCE ,  FISCHETTI VINCENT

IPC: A01N63/00 ,  A61K38/54 ,  C07H21/04 ,  C07K1/00 ,  C12N9/00 ,  C12N15/70 ,  C12P21/06

CPC classification number: A61K38/47 ,  C12Y302/01017

Abstract: A composition and method for treating mastitis by the use of an effective amount of at least one lytic specific for the bacteria causing the disease. The lytic enzyme is genetically coded for by a bacteriophage which may be specific for said bacteria. The enzyme may be at least one lytic protein or peptides in a natural or modified form.

Abstract translation: 一种用于通过使用有效量的至少一种对引起该疾病的细菌特异性的裂解液来治疗乳腺炎的组合物和方法。 裂解酶由可能对所述细菌特异的噬菌体进行遗传编码。 该酶可以是至少一种裂解蛋白或天然或修饰形式的肽。

公开(公告)号：WO2008127419A3

公开(公告)日：2008-12-11

申请号：PCT/US2007084225

申请日：2007-11-09

Applicant: KYTHERA BIOPHARMACEUTICALS INC ,  MUNSHI AMIT ,  DAVID NATHANIEL E

Inventor： MUNSHI AMIT ,  DAVID NATHANIEL E

IPC: A61K39/08 ,  A61K38/48 ,  A61K38/54

CPC classification number: A61K38/4886

Abstract: The present invention discloses compositions and methods for enhancing the effect (e.g., duration) of a neurotoxin treatment. The compositions herein include neurotoxins and neuron growth inhibitors. Such compositions are administered locally to treat or prevent conditions, such as dermatological conditions, urological conditions, thyroid conditions, optical conditions, and neurological conditions.

Abstract translation: 本发明公开了用于增强神经毒素治疗效果（例如持续时间）的组合物和方法。 本文的组合物包括神经毒素和神经元生长抑制剂。 这些组合物局部施用以治疗或预防诸如皮肤病学，泌尿学病症，甲状腺病症，光学病症和神经病症的病症。

公开(公告)号：WO2008143947A1

公开(公告)日：2008-11-27

申请号：PCT/US2008/006251

申请日：2008-05-14

Applicant: UNIVERSITY OF SOUTH FLORIDA ,  KOTHAPALLI, Ravi ,  BISHT, Kirpal, S.

Inventor： KOTHAPALLI, Ravi ,  BISHT, Kirpal, S.

IPC: A61K38/54 ,  A61K38/00 ,  C12N15/12 ,  C07H21/02 ,  C07K7/06

CPC classification number: C07H21/02 ,  C07C233/05 ,  C07C233/65 ,  C07D209/48

Abstract: The present invention concerns farnesylamine derivatives, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of røs-mediated signal transduction and inhibitors of aberrant cell growth, e.g., as anti-cancer agents, as well as anti-fungal agents. Other non-malignant diseases characterized by proliferation of cells that may be treated using the farneylamine derivatives of the include, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.

Abstract translation: 本发明涉及法呢基胺衍生物，含有这些化合物的组合物，以及使用这些化合物和组合物作为rs介导的信号转导抑制剂和异常细胞生长抑制剂的方法，例如作为抗癌剂，以及抗真菌剂 。 以可以使用法呢基胺衍生物治疗的细胞增殖为特征的其它非恶性疾病包括但不限于肝硬化; 移植排斥反应 再狭窄; 和以T细胞增殖为特征的疾病，例如自身免疫性疾病，例如1型糖尿病，狼疮和多发性硬化。

公开(公告)号：WO2008021987A3

公开(公告)日：2008-11-27

申请号：PCT/US2007075630

申请日：2007-08-09

Applicant: BARRON JON

Inventor： BARRON JON

IPC: A61K38/43 ,  A61K38/54 ,  C12N1/00 ,  C12N9/00 ,  C12N9/94

CPC classification number: A61K38/47 ,  A23L29/06 ,  A23L33/17 ,  A61K38/465 ,  A61K38/482 ,  A61K38/4873 ,  A61K2300/00

Abstract: Preferred embodiments of the present invention relate to proteolytic enzyme formulations. More specifically, several embodiments relate a proteolytic formulation comprising fungal protease, papain, bromelain, fungal pancreatin, nattokinase, protease-S, amylase, lipase, rutin, ginger, and CMIK-pH, to facilitate digestion, metabolism, degradation of target compounds, and systemic enzymatic action.

Abstract translation: 本发明的优选实施方案涉及蛋白水解酶制剂。 更具体地说，几个实施方案涉及包含真菌蛋白酶，木瓜蛋白酶，菠萝蛋白酶，真菌胰酶，纳豆激酶，蛋白酶-S，淀粉酶，脂肪酶，芦丁，姜和CMIK-pH的蛋白水解制剂以促进目标化合物的消化，代谢， 和全身酶作用。

公开(公告)号：WO2004100899A3

公开(公告)日：2008-01-17

申请号：PCT/US2004015282

申请日：2004-05-13

Applicant: MCLEAN HOSPITAL CORP ,  YURGELUN-TODD DEBORAH A ,  RENSHAW PERRY F

Inventor： YURGELUN-TODD DEBORAH A ,  RENSHAW PERRY F

IPC: A01N37/18 ,  A61K20060101 ,  A61K38/00 ,  A61K38/22 ,  A61K38/28 ,  A61K38/54 ,  A61K45/06

CPC classification number: A61K45/06 ,  A61K38/2235 ,  A61K2300/00

Abstract: In general, the present invention provides methods for treating disorders associated with the amygdala. The methods of treatment are based on the administration of a therapeutically effective amount of secretin to an individual suffering from a disorder associated with the amygdala, e.g., bipolar disorder or a substance use disorder.

Abstract translation: 通常，本发明提供了治疗与杏仁核有关的疾病的方法。 治疗方法是基于治疗有效量的促胰液素给予患有与杏仁核有关的病症的个体，例如双相情感障碍或物质使用障碍。

公开(公告)号：WO2007075447A2

公开(公告)日：2007-07-05

申请号：PCT/US2006/047967

申请日：2006-12-15

Applicant: OXTHERA, INC. ,  LI, Qingshan ,  SIDHU, Harmeet

Inventor： LI, Qingshan ,  SIDHU, Harmeet

IPC: A61K38/54 ,  A61K38/46 ,  A61K9/14

CPC classification number: A61K9/1652 ,  A61K9/5036 ,  A61K9/5073 ,  A61K9/5089 ,  A61K9/5115 ,  A61K9/5161 ,  A61K9/5192 ,  A61K38/44 ,  A61K38/45 ,  A61K38/488 ,  A61K38/51 ,  A61K47/36 ,  C12Y102/03004 ,  C12Y208/03016 ,  C12Y304/23002 ,  C12Y401/01002 ,  C12Y401/01008 ,  A61K2300/00

Abstract: The present invention comprises methods and compositions for the reduction of oxalate in humans. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing enzymes embedded in particle compositions. The compositions of the present invention are suitable in methods of treatment or prevention of oxalate-related conditions including, but not limited to, hyperoxaluria, absorptive hyperoxaluria, enteric hyperoxaluria, primary hyperoxaluria, idiopathic calcium oxalate kidney stone disease (urolithiasis), vulvodynia, oxalosis associated with end-stage renal disease, cardiac conductance disorders, inflammatory bowel disease, Crohn's disease, ulcerative colitis, and patients who have undergone gastrointestinal surgery and bariatric surgery (surgery for obesity), and/or who have undergone antibiotic treatment.

Abstract translation: 本发明包括用于还原人类中草酸盐的方法和组合物。 例如，本发明提供了用于递送一种或多种包埋在颗粒组合物中的草酸盐还原酶的方法和组合物。 本发明的组合物适用于治疗或预防草酸盐相关病症的方法，包括但不限于高氧尿症，吸收性高氧尿症，肠高氧尿症，原发性高过氧化尿症，特发性草酸钙肾结石病（尿路结石），外阴，草酸病 与终末期肾脏疾病，心脏电导障碍，炎症性肠病，克罗恩病，溃疡性结肠炎以及经历胃肠外科手术和减肥手术（肥胖手术）的患者和/或已进行抗生素治疗的患者相关。

公开(公告)号：WO2004034973A3

公开(公告)日：2007-05-24

申请号：PCT/US0331606

申请日：2003-10-06

Applicant: STERN WARREN

Inventor： STERN WARREN

IPC: A61K31/341 ,  A61K20060101 ,  A61K6/00 ,  A61K31/366 ,  A61K31/4164 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/44 ,  A61K31/557 ,  A61K33/24 ,  A61K38/54 ,  A61L9/04 ,  A61P11/00 ,  A61P11/02

CPC classification number: A61K31/44

Abstract: A method of pharmaceutically managing snoring and impaired breathing is provided. This invention relates to treating snoring, sleep apnea, and other forms of sleep-disordered breathing in those with or without symptoms of or the diagnosis of gastro-intestinal reflux disease (GERD). It comprises administration of a therapeutically effective dose of Prevacid (Lansoprazole) or any other medication that can be used to treat symptoms of hyper-acidity or gastro-intestinal reflux disease (GERD). The therapeutic medication may be used alone or in combination with other pharmacologic agents or mechanical modalities including but not limited to decongestants, antihistamines or mechanical nasal toilet. It also is of benefit in improving breathing disorders that are present while awake.

Abstract translation: 提供了一种药物管理打鼾和受损呼吸的方法。 本发明涉及在有或没有胃肠反流病（GERD）症状或诊断的患者中治疗打鼾，睡眠呼吸暂停和其他形式的睡眠无序呼吸。 其包括施用治疗有效剂量的Prevacid（兰索拉唑）或可用于治疗高酸度或胃肠反流疾病（GERD）症状的任何其它药物。 治疗药物可以单独使用或与其它药物剂或机械方式组合使用，包括但不限于减充血剂，抗组胺剂或机械鼻腔。 它也有益于改善呼吸障碍，同时醒来时。